MedicalSystem Biotechnology Co

MedicalSystem Biotechnology Co P/B

The P/B (Price-to-Book Ratio) of MedicalSystem Biotechnology Co (300439.SZ) as of Nov 6, 2026 is 1.32. In the previous year, P/B (Price-to-Book Ratio) was 1.33 — a change of -0.49% (lower).

P/B

1.32

YoY

-0.49%

Last updated:

P/B (Price-to-Book Ratio) of MedicalSystem Biotechnology Co is 2025 1.32 . P/B (Price-to-Book Ratio) of MedicalSystem Biotechnology Co was 2024 1.33 . It decreases by -0.49% lower compared to the previous year.

The MedicalSystem Biotechnology Co P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
2.09 CNY
Jan 1, 2019
2.92 CNY
Jan 1, 2020
2.38 CNY
Jan 1, 2021
1.66 CNY
Jan 1, 2022
1.55 CNY
Jan 1, 2023
1.44 CNY
Jan 1, 2024
1.33 CNY
Jan 1, 2025
1.32 CNY
The MedicalSystem Biotechnology Co P/B history
YEARP/BYoY
1.32-0.49%
1.33-7.65%
1.44-7.55%
1.55-6.50%
1.66-30.05%
2.38-18.54%
2.92+39.87%
2.09+1.19%
2.06-14.65%
2.41-20.27%
3.03-67.87%
9.43—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

MedicalSystem Biotechnology Co Stock analysis

What does MedicalSystem Biotechnology Co do? MedicalSystem Biotechnology Co., Ltd. generates revenue through the research, development, and manufacturing of bio-tech pharmaceutical products. The company sells in-vitro diagnostic reagents and instruments, along with third-party medical diagnosis services and reagent raw materials. Its primary market is the domestic Chinese market, serving healthcare providers and medical institutions that require diagnostic tools and services. The firm's product portfolio includes in-vitro diagnostic reagent, in-vitro diagnostic instrument, and reagent raw materials, all contributing to its revenue streams. The company focuses on the domestic market, where it provides in-vitro diagnostic products and services to hospitals and clinics. Its diagnostic reagents and instruments are used for medical testing, while the reagent raw materials support manufacturing processes. Third-party medical diagnosis services are offered to clients seeking external testing solutions. The domestic market segment represents the core customer base for MedicalSystem Biotechnology's offerings. MedicalSystem Biotechnology Co., Ltd. operates within the bio-tech pharmaceutical sector, with revenue derived from the sale of diagnostic products and services. The company's in-vitro diagnostic reagent and instrument sales form the backbone of its business, complemented by third-party medical diagnosis services and reagent raw materials distribution. Domestic healthcare institutions are the primary buyers of these products and services, driving the company's financial performance. MedicalSystem Biotechnology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MedicalSystem Biotechnology Co stock

P/B (Price-to-Book Ratio) of MedicalSystem Biotechnology Co is 1.32 in 2025.

P/B (Price-to-Book Ratio) of MedicalSystem Biotechnology Co changed from 1.33 to 1.32, representing a -0.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) MedicalSystem Biotechnology Co since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s MedicalSystem Biotechnology Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — MedicalSystem Biotechnology Co

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — MedicalSystem Biotechnology Co